跳至主要内容
临床试验/NCT02116348
NCT02116348Unknown2 期

Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy

Ain Shams University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年4月最近更新:
适应症
干预措施

试验速览

阶段
2 期
入组人数
100
试验地点
1
主要终点
neurodevelopment

研究概览

简要总结

Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of $11.5 billion or $921,000 average cost per person. Associated disabilities as mental retardation, delayed speech development add psychological burden of the disease on the family as well as economic burden.

Mental retardation is the major problem in children with cerebral palsy. Improving mental development will have a positive effect on quality of life for the child and his family. Treating associated impairments (mental retardation) with Cerebrolysin will improve mental development and quality of life, and will decrease the economic burden in children with cerebral palsy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Cerebral palsy with mental retardation
  • Severe perinatal brain insult

排除标准

  • Severe growth retardation
  • Gastrostomy tube feeding
  • Intractable seizures.
  • Severe motor handicap and deformities from long standing spasticity.
  • Congenital malformations.
  • Suspected inborn error of metabolism.
  • Suspected inherited neurologic disease.
  • Children with auditory and visual impairments.
  • Care giver's refusal to participate in the study.

研究组 & 干预措施

Cerebrolysin

Experimental

Nerve growth factor Cerebrolysin will be given to the intervention group

干预措施: Cerebrolysin (Nerve growth factor) (Drug)

结局指标

主要结局

neurodevelopment

时间窗: 6 months

Intelligence quotient (IQ) assessment at base line and after 3 and 6 month of therapy

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sahar M.A. Hassanein, MD

Professor of Pediatrics

Ain Shams University

研究点 (1)

Loading locations...

相似试验